Fredun Pharmaceuticals Ltd Q3 FY26 Earnings Analysis

- Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years. - Vintage business expected to grow sustainably at around 15% CAGR for the next 7 to 9 years driven by registrations and existing channels. - New age businesses (Pet Care, Nutraceuticals, Mobility) are growing month-on-month with detailed 3 to 7-year plans for each vertical. - Wagr e-commerce platform aims for a multi-million dollar monthly revenue in 5 to 7 years. - By FY'29, management targets INR 90 crores PAT, with potential for higher performance depending on market conditions. - Pet Care division to significantly scale with expansion into 52 countries; strong domestic bases being built to support exports. - Continual product innovation and new SKUs launch to drive working capital needs and revenue growth. - Expansion in manufacturing capacity and distribution enhancing scalability and supporting growth across product lines.

- Fredun Pharmaceuticals expects steady, founded growth with no year of de-growth in the past 18 years, aiming to continue this trajectory. - Vintage business projected to grow sustainably at ~15% CAGR over the next 7 to 9 years. - Management follows a conservative approach, under-promising and aiming to over-deliver on earnings guidance. - PAT guidance of INR 90 crores for FY'29 remains intact, with potential to exceed if outcomes are better than expected. - New age businesses like Pet Care, Nutra, and Mobility have multi-year plans (3 to 7 years) with expected significant revenue contributions. - EBITDA and net profit showed strong growth in Q2 FY26 (EBITDA +60%, PAT +128%) and H1 FY26 (EBITDA +61%, PAT +96%), indicating operational improvements. - Long-term vision includes expanding US business to contribute over 51% of revenue by FY 2032. - Continued investment in new product development, marketing, and team-building to support growth.

- Fredun Pharmaceuticals plans capex and strategic investments primarily for new product development, team building, marketing, and distribution. - Recent fundraising will be used as growth capital to accelerate sustainable growth in new age businesses towards 2029-2030. - Planned investments include INR4-5 crores over the next 18-24 months and another INR5-7 crores later for the Wagr e-commerce platform to align and promote sales. - The company is expanding manufacturing capacity with a state-of-the-art facility at Palghar and adding contract manufacturing locations to support product portfolio growth. - Capex also includes infrastructure to increase production, especially for nutraceuticals, mobility, cosmetics, and pet care products. - The acquisition of Wagr.ai was a zero-cash cost deal, focusing investment on platform development rather than acquisition price. - Hiring and building a robust human resource infrastructure across different brands and verticals is a key ongoing strategic investment.

- No explicit mention of any new fundraising through debt or equity in the provided transcript. - The company recently completed a fundraising round, the proceeds of which are allocated for new product development, team building, marketing, distribution, capex, working capital, and reserves. - The funds raised are aimed at accelerating growth in new age businesses while vintage business grows steadily. - No indication of plans for raising additional debt or equity in the near term was discussed during the call. - Focus is currently on utilizing existing raised funds efficiently towards sustainable growth and expansion.

- Fredun Pharmaceuticals has received an "unbelievable" and "crazy phenomenal" response for their Snacky Jain product. - The order book for Snacky Jain has surpassed their initial expectations. - Due to high demand, they had to revisit manufacturing and procurement plans. - Snacky Jain is expected to be in stores across certain geographies by the end of November 2025. - Within the next 6 months, it is planned to be available in most parts of India. - They are receiving multiple daily requests for entire stock purchases from customers. - Plans to launch more variants of Snacky Jain targeting different nutritional and health needs (gut health, mobility health, geriatric dogs, young dogs) to cater to the demand.